Use of OM-85 BV for the prevention of acute respiratory tract infections in occupational medicine.
This study evaluated the safety and efficacy of the immunostimulatory agent OM-85 BV in 112 male car-factory workers who were highly susceptible to acute respiratory tract infections (ARTIs), each having experienced > or = 4 ARTIs during 1999. From January to March 2000, each worker received one capsule of OM-85 BV (7 mg) per day for 10 consecutive days each month. The patients were followed for a further 9 months. Mean number of ARTIs decreased from 8.2 +/- 2.1 per worker in 1999 to 5.3 +/- 2.9 in 2000; i.e. a difference of -2.9 (95% confidence intervals, -3.5 to -2.4). Similar effects were observed in men who had different job roles, and no adverse events were reported during drug administration. We concluded that OM-85 BV appears to be safe and effective in reducing the incidence of ARTIs in susceptible workers, although further double-blind, placebo-controlled clinical trials are required.
Carmona-Ramírez
M A
MA
Department of Occupational Medicine, Ford Motor Company, Cuautitlan Unity, Cuautitlan, Mexico.
Alvárez-Gómez
V
V
Berber
A
A
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D001419:Bacteria; D002457:Cell Extracts; D006801:Humans; D007369:Interferon Inducers / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009784:Occupational Diseases / Q000517:prevention & control*; D011446:Prospective Studies; D012141:Respiratory Tract Infections / Q000517:prevention & control*; D000095983:Bacterial Lysates
D000276:Adjuvants, Immunologic; D002457:Cell Extracts; D007369:Interferon Inducers; C030259:Broncho-Vaxom; D000095983:Bacterial Lysates